- Mitsubishi UFJ Asset Management increased its stake in Regeneron by 5.1% to 209,063 shares, worth about $109.76 million (roughly 0.19% of the company) at quarter-end.
- Wall Street sentiment is broadly positive with a consensus rating of “Moderate Buy” and an average price target of $796.57 (three Strong Buy, fifteen Buy, seven Hold, one Sell).
- Regeneron recently beat estimates with quarterly EPS of $11.83 and revenue of $3.75 billion, and announced a quarterly dividend of $0.88 per share (annualized $3.52, ~0.5% yield).
Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 209,063 shares of the biopharmaceutical company’s stock after purchasing an additional 10,213 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.19% of Regeneron Pharmaceuticals worth $109,758,000 at the end of the most recent quarter.
- Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
Several other institutional investors also recently added to or reduced their stakes in the business. Activest Wealth Management grew its position in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares during the last quarter. Costello Asset Management INC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $27,000. Saudi Central Bank bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $31,000. Finally, Colonial Trust Advisors bought a new position in Regeneron Pharmaceuticals during the first quarter valued at about $32,000. 83.31% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on REGN. Bank of America lifted their target price on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a research report on Wednesday, October 29th. Citigroup increased their target price on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Sanford C. Bernstein raised their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Finally, BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research note on Monday, August 4th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $796.57.
Regeneron Pharmaceuticals Stock Performance
Shares of NASDAQ:REGN opened at $657.53 on Friday. The firm has a market cap of $69.69 billion, a PE ratio of 15.75, a PEG ratio of 2.03 and a beta of 0.31. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The company’s 50 day moving average price is $588.03 and its two-hundred day moving average price is $568.04. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $834.42.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating the consensus estimate of $9.73 by $2.10. The business had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s revenue was up .9% on a year-over-year basis. During the same period in the previous year, the business earned $12.46 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.
Insider Transactions at Regeneron Pharmaceuticals
In other news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 7.02% of the stock is currently owned by insiders.
